Personalizing treatment of transfusion-dependent anemia in LR-MDS 

Matteo Della Porta, MD, IRCCS Humanitas Research Hospital, Milan, Italy, discusses the potential of personalized medicine for treating transfusion-dependent anemia in lower-risk myelodysplastic syndromes (LR-MDS). He explains that treatment can be tailored based on the mechanism of ineffective hematopoiesis. For instance, patients with 5q deletions may respond well to lenalidomide, while those with splicing-related mutations may benefit more from luspatercept. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.